Advertisement
Advertisement
April 13, 2021
Endologix Acquires PQ Bypass
April 13, 2021—Endologix LLC announced it has completed the acquisition of PQ Bypass, Inc., which is based in Miliptas, California. Endologix is headquartered in Irvine, California.
The company noted that the PQ Bypass Detour platform for percutaneous femoropopliteal bypass was designated as an FDA Breakthrough Device in September 2020. The Detour system, which consists of the Torus stent graft and the PQ crossing device, is being studied in the United States and Europe in the DETOUR2 clinical trial.
Richard Mott, Chief Executive Officer and Chairman of Endologix, commented in the company’s announcement, “The acquisition of PQ Bypass is a seminal moment in Endologix’s history, building upon our leadership in the treatment of abdominal aortic aneurysm to champion disruptive technologies for the treatment of vascular disease. We intend to actively pursue new and innovative vascular technologies that are clinically relevant to surgeons, hospitals, and patients, with a commitment to world-class medical education, clinical research, and excellent procedural outcomes.”
Advertisement
Advertisement
